Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932523 | 0.81 | — | — | |
| SCHEMBL9876428 | 0.78 | — | — | |
| SCHEMBL11923804 | 0.77 | FFAR3 (0.38) | GAAFFAR3KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL1944466 | 0.77 | FFAR3 (0.65) | GAAFFAR3KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL2279732 | 0.76 | — | — | |
| SCHEMBL1938094 | 0.76 | — | — | |
| SCHEMBL14932767 | 0.75 | — | — | |
| SCHEMBL1870649 | 0.75 | FFAR3 (0.36) | GAAFFAR3KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL651351 | 0.74 | ALDH1A1 (0.42) | FFAR3SMN1; SMN2 | |
| SCHEMBL246831 | 0.74 | ALDH1A1 (0.42) | FFAR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263405-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | VALO HEALTH, INC. | 2025-08-21 | — | — | US | disclosed |
| EP-4426285-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | Valo Health, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024026424-A1 | QUINAZOLINONE DERIVATIVES AS AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023081328-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | VALO HEALTH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081328-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | VALO HEALTH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2021057890-A1 | 2H-BENZOPYRAN DERIVATIVES AS CRAC INHIBITORS | 南京明德新药研发有限公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263405-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | GAA 98/4885FFAR3 3889/4885KDM4E 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.